Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
Aviva is a Top 4 Provider of Private Medical Insurance in the UK
Aviva是英國前四大私人醫療保險提供商
By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care Market
加入AXA後,在大倫敦脊柱護理市場上,約45%的私人醫療保險患者現在可以使用Nociscan
BROOMFIELD, CO, July 09, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today an additional key milestone with their second payer coverage of Nociscan by Aviva in London, UK in conjunction with The London Clinic, one of the UK's largest and most renowned independent hospitals. Aviva is a leading provider of private medical insurance in the UK and joins private medical insurance provider, AXA, in covering Nociscan for patients suffering from chronic low back pain.
2024年7月9日,科技醫療公司Aclarion, Inc.(以下簡稱公司)(納斯達克代碼:ACON, ACONW),利用生物標誌和專有的人工智能算法,幫助醫生確定慢性腰痛位置的公司,宣佈與英國Aviva在倫敦與英國最大最著名的獨立醫院之一,倫敦診所合作。 Aviva是英國領先的私人醫療保險提供商,在患有慢性腰痛的患者中,加入了私人醫療保險提供商AXA,一同爲Nociscan提供保障。
"This second payer coverage decision builds the momentum we expect to see in markets once one payer recognizes the advantages of paying for Nociscan," said Brent Ness, CEO of Aclarion. "When you look at other diagnostic companies that market imaging combined with AI decision support solutions, you tend to see steady product adoption and value creation once payer coverage decisions are secured. HeartFlow in the cardiology space is a perfect example. Similar to Aclarion, they received their first payer coverage decision in the UK and were able to parlay that into a steady march towards standard of care and tremendous value creation for investors. I was a member of the early commercial development team at HeartFlow and intend to apply the same successful formula to Aclarion where we are addressing the larger market of low back pain. We welcome the second vote of confidence and key validation from UK payers and look forward to more."
「這次第二批付費人士覆蓋決策推動了我們在市場上看到的勢能。一旦有一個付費人士意識到支付Nociscan的優勢,您會看到其他市場中的診斷公司向市場推廣與人工智能決策支持解決方案相結合的影像產品,這 tend 趨於看到穩定的產品採用率和價值創造。在心臟病學領域,HeartFlow是一個完美的例子。類似於Aclarion,他們在英國獲得了第一個付費者覆蓋決策,並能夠將其轉化爲穩定的走向標準療法和投資者巨大的價值創造。我是 HeartFlow 早期商業發展團隊的成員,並打算將這種成功的公式應用於 Aclarion,我們正在解決更大的腰痛市場。我們歡迎付費人士的第二次信任和關鍵確認,並期待更多。」
In the UK, self-pay and private medical insurance are estimated to represent nearly 70% of private hospital revenues, with private medical insurance becoming increasingly popular. Aviva is one of the four leading private medical insurers in the UK with an estimated 14% of the private medical insurance market and an estimated 1.2 million insured customers. By joining AXA, the 2 nd largest private medical insurer with roughly a 30% market share and 3 million covered lives, Nociscan is now available to 45% of patients with private insurance in the greater London area.
在英國,自費和私人醫療保險預計佔私人醫院收入的近70%,而私人醫療保險變得越來越流行。 Aviva是英國四大領先的私人醫療保險公司之一,估計持有該市場14%的私人醫療保險市場份額,約120萬保險客戶。與具有大約30%市場份額和300萬被保險人的第二大私人醫療保險公司AXA合併後,Nociscan現在可供大倫敦地區45%的私人醫療保險患者使用。
The London Clinic and their expert spine physicians have adopted Nociscan as an important decision support tool to be used when diagnosing and treating their chronic low back pain patients. Low back pain has been estimated to affect up to one third of the UK adult population each year. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain.
The London Clinic及其專家脊柱醫師已將Nociscan作爲重要的決策支持工具,用於診斷和治療慢性腰痛患者,據估計,腰痛每年影響英國成年人口達三分之一。Aclarion的Nociscan解決方案是第一款有證據支持的SaaS平台,可以在腰椎區域非侵入性地幫助醫生區分有痛感和無痛感的椎間盤。Nociscan客觀的量化了與椎間盤疼痛有關的化學生物標誌物,然後將其投入專有的算法中,以確定是否會造成疼痛。當與其他診斷工具一起使用時,Nociscan提供了關於患者腰痛位置的重要見解。
For more information about The London Clinic, please visit:
更多關於倫敦診所的信息,請訪問:
For more information about the London Spine Clinic, please visit:
更多關於倫敦脊椎診所的信息,請訪問:
About Aclarion, Inc.
關於Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit .
Aclarion是一家醫療技術公司,利用磁共振波譜("MRS")、專有信號處理技術、生物標誌物和增強型智能算法等技術優化臨床醫療治療。該公司首先利用Nociscan服務解決慢性腰痛問題,這是第一個有證據支持的SaaS平台,可在腰椎區域非侵入性地幫助醫生區分有痛感和無痛感的椎間盤。通過雲連接,Nociscan可以接收每個需評估的腰椎盤的核磁共振波譜(MRS)數據。在雲端,專有的信號處理技術可以提取並量化化學生物標誌物,這些標誌物已被證明與椎間盤疼痛有關。然後將生物標誌物數據投入專有算法中,以判斷椎間盤是否會造成疼痛。當與其他診斷工具一起使用時,Nociscan提供了關於患者腰痛位置的重要見解,使醫生可以明確治療策略。
Forward Looking Statements
前瞻性聲明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
本新聞稿包含Aclarion對公司當前的結果、表現、前途和機遇等方面的前瞻性聲明,以及與1933年證券法第27A條和1934年證券交易法第21E條、《私募證券訴訟改革法》(Private Securities Litigation Reform Act of 1995)有關的內容。諸如「預計」、「相信」和「期望」等表達方式的、非歷史事實的描述均屬於本新聞稿中的前瞻性聲明。這些前瞻性聲明基於管理層的當前計劃和期望,並受到許多不確定因素和風險的影響,這些因素和風險可能會極大地影響公司當前計劃和期望,以及未來的經營業績和財務狀況。更多的風險和不確定性在我們向證券交易委員會提交的文件中得到了更充分的討論,鼓勵讀者閱讀《風險因素》部分,該部分載於公司包括2023年12月31日於年度報告的Form 10-k以及其他在證券交易委員會提交的文件中包含的披露文件中。前瞻性聲明所含的內容與本日相符,公司無義務公開更新或修訂任何前瞻性聲明,不論是因爲獲得新信息、未來事件或其他原因。
Disclosure
披露聲明
The information stated above was prepared by Aclarion and reflects solely the opinion of Aclarion. Nothing in this statement shall be construed to imply any support or endorsement of Aclarion or any of its products by The London Clinic.
上述信息由Aclarion準備,僅反映Aclarion的觀點。本聲明中的任何內容都不應被解釋爲暗示The London Clinic對Aclarion或其任何產品的支持或認可。
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
投資者聯繫人:查看更多信息前往:
Kirin m. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
媒體聯繫人:
Jodi Lamberti
SPRIG諮詢公司
612.812.7477
jodi@sprigconsulting.com